Clinical Trials

Click here to go to clinicaltrials.gov

 

View Tips and Talking Points for Supporting a Patient’s Decision
to Enroll in a Clinical Trial Here

 

Featured Clinical Trials

UF Health Cancer Center

UF Health Cancer Center Clinical Trials

With more than 150 clinical trials open and currently recruiting patients, the UF Health Center has numerous options for patients with refractory malignancies. The February issue of the UF Health Cancer Center Navigator highlights a few of them. For a complete listing of trials available through our system, please click below. View all UF Health...

Gainesville Cancer Center Offers Community Trial Navigation for Local Clinical Research Trials

GAINESVILLE, FL – March 28th, 2018. . . . Florida Cancer Specialists & Research Institute (FCS), is pleased to announce the availability of a local Trial Navigator at Gainesville Cancer Center(GCC), located at 6420 W. Newberry Road, East Wing-Suite 100, Gainesville, FL.  Offering comprehensive care and a wide range of treatments, Gainesville Cancer Center has an established record of broad clinical research...

ENVISION Phase 3 Study

Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP). Trial Status: Enrolling Interested in learning more? Please email us at [email protected] For more info: ClinicalTrials.gov – NCT03338816

New Data vs Bicalutamide

Indication XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Important Safety Information Contraindications  XTANDI is not indicated for women. XTANDI can cause fetal harm and potential loss of pregnancy. Warnings and Precautions Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In placebo-controlled studies, 8 of 1671...

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

  AbbVie and Bristol-Myers Squibb Company  announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). The Phase 1/2...

New Gynecologic Oncology Clinical Trials Sylvester Comp Cancer Center Sylvester Comp Cancer Center

The Sylvester Comprehensive Cancer Center’s Division of Gynecologic Oncology’s Research Program is opening 4 new clinical trials for women with ovarian, cervical and endometrial cancer. These include two surgical trials evaluating the role of sentinel lymph node biopsy in cervical and endometrial cancer and two immunotherapy trials in first-line and recurrent ovarian cancer. They continue...

Available Clinical Trials at UF Health Cancer Center

UF Health Cancer Center has several clinical trials in process, below please find information about four trials that are currently accepting participants: ADU-CL-11 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer. https://clinicaltrials.gov/ct2/show/NCT02575807?term=adu-cl-11&rank=1  ARGO A Phase III Randomized Placebo-Controlled Study Evaluating...

Florida Hospital Clinical Trial GL-ONC1-015: Phase 1b Study with GL-ONC1 Oncolytic Immunotherapy in Patients with Platinum-resistant or Refractory Ovarian Cancer

New Clinical Trials Available at FHCI: Ovarian Cancer and peritoneal carcinomatosis: GL-ONC1-015: This is an open-label, non-randomized Phase 1b study evaluating the safety and immunotherapeutic effect of GL-ONC1, an oncolytic vaccinia virus, in women diagnosed with platinum-resistant ovarian cancer and peritoneal carcinomatosis. GL-ONC1 is administered via an intraperitoneal catheter. https://clinicaltrials.gov/ct2/show/NCT02759588?term=GL-ONC1&rank=2   Clinical Trial Profile: Clinical...

UF Health

The UF Health Cancer Center Clinical Trial mobile app is here!

NaviGATOR makes it easier to search for and find clinical trials that fit you and your patients’ needs. This powerful and easy-to-navigate application helps you quickly learn about the availability of clinical trials from UF Health Cancer Center. And with one-tap your patient can be referred to UF Health Cancer Center. [su_button url=”http://trials.cancer.ufl.edu/” target=”blank” style=”flat”...

lynn cancer institute

Lynn Cancer Institute Oncology Trials

Clinical Trials – November 2015 Eugene M. and Christine E. Lynn Office of Research Administration 561.955.4800 Center for Hematology-Oncology 561.955.6400 Radiation Oncology 561.955.4111 BREAST Primary Site Sponsor/Study ID NCT # Protocol Description Eligibility Breast HER2 + MBC third line PUMA- NER-1301 NALA NCT01808573 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients...

spohnc

Support for People With Oral and Head and Neck Cancer

“Find a Clinical Trial for Oral, Head and Neck Cancer” Call toll-free 844-432-3888 (Mon-Fri, 9 am -5 pm ET) SPOHNC is pleased to introduce EmergingMed’s Clinical Trial Navigation Service. We want you to be aware of all of your treatment options. SPOHNC has partnered with EmergingMed to offer you a way to take action. The...

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update Boehringer Ingelheim Pharmaceuticals, Inc. would like to share the overall survival (OS) data from a head-to-head Phase III clinical trial that was recently published in The Lancet Oncology. The study evaluated the company’s lung cancer treatment as a potential option for patients with advanced...

Head-to-Head Efficacy and Safety Results in First-Line CLL

CLL-11: Designed to determine the superior anti-CD20 regimen for typical* patients1-4 CLL-11 is a Phase III trial that evaluated GAZYVA + Clb against rituximab + Clb to establish a first-line treatment for typical CLL patients, based on age and coexisting medical conditions1-4 The safety and efficacy of GAZYVA + Clb was evaluated in a Stage...

© 2020 FLASCO | Premium Website Design by The HDG

FLASCO